371-P: Sex, Age, and Diabetes Type—Dissecting Patterns of Real-World Level 3 Hypoglycemia (iNPHORM, USA)

by sugaradmin



Introduction and Objective: Large-scale, real-world data on age- and sex-specific Level 3 hypoglycemia rates in type 1 or 2 diabetes (T1D, T2D) remain critically sparse. We aimed to address this gap using prospective data from the iNPHORM study.Methods: Adults (≥18 years) with T1D or T2D on insulin and/or secretagogues recruited from a US-wide probability-based internet panel completed an online screener, baseline, and up to 12 monthly follow-up questionnaires. For complete cases with ≥1 follow-up, we calculated annualized Level 3 hypoglycemia rates overall and by age, sex (assigned-at-birth), and diabetes type.Results: N=978 participants were analyzed; Table 1 reports overall and group-specific Level 3 hypoglycemia rates. Across diabetes types, adults aged 18-39 years—particularly males—reported the highest event rates, which sharply dropped after age 39, regardless of sex. In T1D, females aged 40-49 years had higher rates than males (p=0.04), a trend that persisted (non-significantly) in cohorts aged ≥60 years. In T2D, males had higher Level 3 hypoglycemia rates than females until after age 59, when increasing female rates surpassed (non-significantly) declining male rates.Conclusion: Our results reveal age- and sex-based disparities in Level 3 hypoglycemia, suggesting that younger males and older females are key at-risk groups. Targeted prevention strategies are crucial to ensure equitable outcomes across diverse populations with diabetes.

Disclosure

A. Ratzki-Leewing: Other Relationship; Abbott, Dexcom, Inc. Consultant; Sanofi. Other Relationship; Sanofi. Consultant; Sanofi-Aventis U.S. Advisory Panel; Sanofi-Aventis U.S. J.E. Black: None. A. Kahkoska: None. K. Gandhi: None. B.L. Ryan: None. G. Zou: None. S.B. Harris: Advisory Panel; Abbott. Consultant; Abbott. Research Support; Boehringer-Ingelheim. Advisory Panel; Dexcom, Inc. Consultant; Dexcom, Inc. Research Support; Canadian Institutes of Health Research. Advisory Panel; Eli Lilly and Company. Research Support; Eli Lilly and Company. Consultant; Medscape. Advisory Panel; Novo Nordisk. Research Support; Novo Nordisk, Novartis Pharmaceuticals Corporation. Advisory Panel; Sanofi. Consultant; Sanofi.

Funding

The iNPHORM study was funded through an investigator-initiated grant from Sanofi Global.



Source link